^
    4ms
    Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov)
    P1, N=140, Terminated, Merck Sharp & Dohme LLC | Completed --> Terminated; Business Reasons
    Trial termination • Combination therapy • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • MK-2118
    almost2years
    Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov)
    P1, N=140, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • MK-2118
    2years
    Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov)
    P1, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: May 2023 --> Jan 2023 | Trial primary completion date: May 2023 --> Jan 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • MK-2118
    over2years
    Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov)
    P1, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> May 2023 | Trial primary completion date: Oct 2022 --> May 2023
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • MK-2118
    over2years
    Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov)
    P1, N=160, Recruiting, Merck Sharp & Dohme Corp. | Trial completion date: Jun 2022 --> Oct 2022 | Trial primary completion date: Jun 2022 --> Oct 2022
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • MK-2118